Cullinan Therapeutics, Inc.
CGEMNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $860.90M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.73$23.19
- Volume (live)
- -
- Avg. volume (3M)
- 1.17M
Cullinan Therapeutics (CGEM) Stock Price & Financial Analysis
Cullinan Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $13.46 - $14.18 |
|---|---|
| 52-Week High | $23.19 |
| 52-Week Low | $6.73 |
| Open | $13.62 |
| Volume (last close) | 972.11K |
| Average Volume (3M) | 1.17M |
| 50-Day MA | $19.12 |
|---|---|
| 200-Day MA | $15.56 |
| 1-Year Change | +60.18% |
| Market Cap | 860.90M |
|---|---|
| Shares Outstanding | 61.49M |
| Price to Book (P/B) | 2.68 |
| EV/EBITDA | -3.54 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Cullinan Therapeutics at a Glance
As of the Oct 15, 2026 close, Cullinan Therapeutics (CGEM) has a market capitalization of $860.90M.
As of its latest reported balance sheet, it holds $78.64M in cash and securities against $2.07M of debt, a net cash position of $76.57M.
Cullinan Therapeutics does not currently pay a dividend.
The share price is up 60.2% over the past year. At $14.00 (the Oct 15, 2026 close) it sits within its 52-week range of $6.73 to $23.19, below its 200-day moving average of $15.56.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $35.70, 155.0% above the Oct 15, 2026 close.
Frequently Asked Questions About Cullinan Therapeutics
What is the current stock price for CGEM?
As of the Oct 15, 2026 close, CGEM stock trades at $14.00. The 52-week range is $6.73–$23.19, with a day range of $13.46–$14.18.
What is the P/E ratio for CGEM?
The P/E ratio (Price-to-Earnings) for CGEM is shown in the Key Statistics section. This valuation metric helps compare Cullinan Therapeutics, Inc. to industry peers.
Does CGEM pay dividends?
Cullinan Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CGEM?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for CGEM is Buy. The average 12-month price target is $35.70, a 155.0% upside from the Oct 15, 2026 close of $14.00.
What is the market cap of CGEM?
As of the Oct 15, 2026 close, Cullinan Therapeutics's market capitalization is $860.9M, classifying it as a small-cap company. Cullinan Therapeutics operates in the Healthcare sector within the Biotechnology industry.